Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
暂无分享,去创建一个
Hakho Lee | Ralph Weissleder | Soldano Ferrone | Cesar M. Castro | Hyungsoon Im | Chen-Han Huang | Cesar M Castro | Seonki Hong | Hakho Lee | Seonki Hong | R. Weissleder | Chen-Han Huang | S. Ferrone | H. Im | Katherine S Yang | C. D. del Castillo | Rui Wang | S. Clardy | I. Pergolini | Rui Wang | Ilaria Pergolini | Andres Fernandez Del Castillo | Susan Clardy | Craig Pille | Robert Yang | Carlos Fernandez Del Castillo | Katherine S. Yang | Craig Pille | Robert Yang | R. Yang | Andres Fernandez del Castillo | Susan M. Clardy
[1] H. Kocher,et al. Pancreatic Cancer , 2019, Methods in Molecular Biology.
[2] Rajesh Aggarwal,et al. Simulation Research in Gastrointestinal and Urologic Care—Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop , 2018, Annals of surgery.
[3] S. Hanash,et al. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. , 2016, Journal of the National Cancer Institute.
[4] J. Berlin,et al. Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. , 2016, JAMA oncology.
[5] S. Nagrath,et al. Opportunities and Challenges for Pancreatic Circulating Tumor Cells. , 2016, Gastroenterology.
[6] J. Weitz,et al. Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer , 2016, Langenbeck's Archives of Surgery.
[7] J. Manson,et al. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. , 2016, Journal of the National Cancer Institute.
[8] Melissa M. Sprachman,et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle–B cell interactions , 2016, Science.
[9] L. Bujanda,et al. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. , 2016, Annals of translational medicine.
[10] J. Mayerle,et al. Pancreatic cancer in 2015: Precision medicine in pancreatic cancer — fact or fiction? , 2016, Nature Reviews Gastroenterology &Hepatology.
[11] E. Diamandis,et al. Glypican-1 as a highly sensitive and specific pancreatic cancer biomarker , 2016, Clinical chemistry and laboratory medicine.
[12] C. Ferrone,et al. Intracellular antigens as targets for antibody based immunotherapy of malignant diseases , 2015, Molecular oncology.
[13] Vikesh K. Singh,et al. Advances in Biomedical Imaging, Bioengineering, and Related Technologies for the Development of Biomarkers of Pancreatic Disease: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Biomedical Imaging and Bioengineering Workshop , 2015, Pancreas.
[14] D. Metz,et al. Consensus on biomarkers for neuroendocrine tumour disease. , 2015, The Lancet. Oncology.
[15] Gemma K. Alderton. Diagnosis: Fishing for exosomes , 2015, Nature Reviews. Cancer.
[16] Honghe Zhang,et al. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. , 2015, International journal of clinical and experimental medicine.
[17] Christian Pilarsky,et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.
[18] Clotilde Théry,et al. Cancer: Diagnosis by extracellular vesicles , 2015, Nature.
[19] M. Büchler,et al. Combined evaluation of a panel of protein and miRNA serum‐exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity , 2015, International journal of cancer.
[20] Michael A. Hollingsworth,et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver , 2015, Nature Cell Biology.
[21] Bob S. Carter,et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma , 2015, Nature Communications.
[22] Honghe Zhang,et al. Tumor markers CA 19-9 , CA 242 and CEA in the diagnosis of pancreatic cancer : a meta-analysis , 2015 .
[23] W. Schmiegel,et al. New insights in the composition of extracellular vesicles from pancreatic cancer cells: implications for biomarkers and functions , 2014, Proteome Science.
[24] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[25] Hakho Lee,et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor , 2014, Nature Biotechnology.
[26] C. Landen,et al. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. , 2013, Gynecologic oncology.
[27] C. Borrebaeck,et al. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature , 2013, International journal of cancer.
[28] Kimberly A Kelly,et al. Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.
[29] Jun Li,et al. TCPA: a resource for cancer functional proteomics data , 2013, Nature Methods.
[30] Mohid S. Khan,et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Chris Gardiner,et al. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis , 2013, Journal of extracellular vesicles.
[32] Hakho Lee,et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy , 2012, Nature Medicine.
[33] Akhilesh Pandey,et al. Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). , 2012, Journal of proteome research.
[34] W. Greenhalf,et al. New biomarkers and targets in pancreatic cancer and their application to treatment , 2012, Nature Reviews Gastroenterology &Hepatology.
[35] K. Matsuo,et al. Seven-Signal Proteomic Signature for Detection of Operable Pancreatic Ductal Adenocarcinoma and Their Discrimination from Autoimmune Pancreatitis , 2012, International journal of proteomics.
[36] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[37] Hakho Lee,et al. Micro-NMR for Rapid Molecular Analysis of Human Tumor Samples , 2011, Science Translational Medicine.
[38] M. Duffy,et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[39] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[40] D. Tan,et al. Diagnostic and prognostic biomarkers in pancreatic carcinoma. , 2009, International journal of clinical and experimental pathology.
[41] Michelle A. Anderson,et al. A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.
[42] F. Schmidt. Meta-Analysis , 2008 .
[43] H. Zou,et al. Regularization and variable selection via the elastic net , 2005 .
[44] D. Chan,et al. Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.
[45] R. Tibshirani. Regression Shrinkage and Selection via the Lasso , 1996 .
[46] J. Sengupta. The Nonparametric Approach , 1989 .
[47] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[48] S. Ferrone,et al. A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. , 1982, Journal of the National Cancer Institute.